PE20061328A1 - Derivados de oxadiazol o tiadiazol como inhibidores de la biosintesis de leucotrienos - Google Patents
Derivados de oxadiazol o tiadiazol como inhibidores de la biosintesis de leucotrienosInfo
- Publication number
- PE20061328A1 PE20061328A1 PE2006000290A PE2006000290A PE20061328A1 PE 20061328 A1 PE20061328 A1 PE 20061328A1 PE 2006000290 A PE2006000290 A PE 2006000290A PE 2006000290 A PE2006000290 A PE 2006000290A PE 20061328 A1 PE20061328 A1 PE 20061328A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- tiadiazole
- oxadiazole
- biosynthesis
- inhibitors
- Prior art date
Links
- 230000015572 biosynthetic process Effects 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 150000004866 oxadiazoles Chemical class 0.000 title 1
- -1 4-FLUOROPHENYL Chemical class 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 2
- WZKSXHQDXQKIQJ-UHFFFAOYSA-N F[C](F)F Chemical class F[C](F)F WZKSXHQDXQKIQJ-UHFFFAOYSA-N 0.000 abstract 2
- OCBFFGCSTGGPSQ-UHFFFAOYSA-N [CH2]CC Chemical compound [CH2]CC OCBFFGCSTGGPSQ-UHFFFAOYSA-N 0.000 abstract 2
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical class [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- 229910052717 sulfur Chemical group 0.000 abstract 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 abstract 1
- 230000003266 anti-allergic effect Effects 0.000 abstract 1
- 230000003110 anti-inflammatory effect Effects 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- KXDAEFPNCMNJSK-UHFFFAOYSA-N benzene carboxamide Natural products NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 150000002617 leukotrienes Chemical class 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen(.) Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000011593 sulfur Chemical group 0.000 abstract 1
- 239000011701 zinc Substances 0.000 abstract 1
- 229910052725 zinc Inorganic materials 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Reproductive Health (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Toxicology (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Gynecology & Obstetrics (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pregnancy & Childbirth (AREA)
- Dermatology (AREA)
- Transplantation (AREA)
- Gastroenterology & Hepatology (AREA)
- Ophthalmology & Optometry (AREA)
- Communicable Diseases (AREA)
- Orthopedic Medicine & Surgery (AREA)
Abstract
REFERIDA A UN COMPUESTO DERIVADO DE OXADIAZOL O TIADIAZOL DE FORMULA 1a, DONDE LA LINEA PUNTEADA SIGNIFICA UN ENLACE DOBLE O SIMPLE; A ES (a) UN ANILLO AROMATICO DE CINCO MIEMBROS QUE CONTIENE UNO O MAS ATOMOS DE CARBONO, UN HETEROATOMO SELECCIONADO A PARTIR DE OXIGENO Y AZUFRE Y DE CERO A TRES ATOMOS DE NITROGENO, (b) UN ANILLO AROMATICO DE CINCO MIEMBROS QUE CONTIENE UNO O MAS ATOMOS DE CARBONO Y DE UNO A CUATRO ATOMOS DE NITROGENO, ENTRE OTROS; X ES O O S; Y ES S, O, ENTRE OTROS; R1 ES H, ALQUILO C1-C6, CICLOALQUILO C3-C6; R2 ES H, OH, F, ALQUILO C1-C3, ENTRE OTROS; R3 ES H, ALQUILO C1-C6, ENTRE OTROS; R4 ES H, ALQUILO C1-C6, ENTRE OTROS; R5 ESTA AUSENTE O ES ALQUILO C1-C6, CICLOALQUILO C3-C6 O HALO. SON COMPUESTOS PREFERIDOS: 4-BROMO-N-{[4-(4-FLUOROFENIL)-2-OXO-2H-CROMEN-7-IL]METIL}-N-{5-[1-HIDROXI-1-(TRIFLUOROMETIL)PROPIL]-1,3,4-OXADIAZOL-2-IL}BENZAMIDA, 4-(4--FLUOROFENIL)-7-{[{5-[1-HIDROXI-1-(TRIFLUOROMETIL)PROPIL]-1,3,4-OXADIAZOL-2-IL}(ISOPROPIL)AMINO]METIL}-2H-CROMEN-2-ONA, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE LA BIOSINTESIS DE LEUCOTRIENOS Y SON UTILES COMO AGENTES ANTIATEROSCLEROTICOS, ANTIASMATICOS, ANTIALERGICOS, ANTIINFLAMATORIOS Y CITOPROTECTORES
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US66431705P | 2005-03-23 | 2005-03-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20061328A1 true PE20061328A1 (es) | 2007-01-13 |
Family
ID=37023348
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2006000290A PE20061328A1 (es) | 2005-03-23 | 2006-03-16 | Derivados de oxadiazol o tiadiazol como inhibidores de la biosintesis de leucotrienos |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US20090227638A1 (es) |
| EP (1) | EP1869031B1 (es) |
| JP (2) | JP4109316B1 (es) |
| KR (1) | KR20070113259A (es) |
| CN (2) | CN101146802A (es) |
| AR (1) | AR055041A1 (es) |
| AU (1) | AU2006227524B2 (es) |
| BR (1) | BRPI0609687A2 (es) |
| CA (1) | CA2600727C (es) |
| CR (1) | CR9442A (es) |
| DO (1) | DOP2006000069A (es) |
| EA (1) | EA012704B1 (es) |
| ES (1) | ES2394179T3 (es) |
| GT (1) | GT200600117A (es) |
| IL (1) | IL185724A0 (es) |
| MA (1) | MA29398B1 (es) |
| MX (1) | MX2007011638A (es) |
| MY (1) | MY142105A (es) |
| NI (1) | NI200700242A (es) |
| NO (1) | NO20075384L (es) |
| PA (1) | PA8667201A1 (es) |
| PE (1) | PE20061328A1 (es) |
| TN (1) | TNSN07348A1 (es) |
| TW (1) | TWI321130B (es) |
| WO (1) | WO2006099735A1 (es) |
| ZA (1) | ZA200707385B (es) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR055041A1 (es) * | 2005-03-23 | 2007-08-01 | Merck Frosst Canada Ltd | Tiadiazoles y oxadiazoles como inhibidores de la sintesis de leucotrienos. composiciones farmaceuticas. |
| WO2007038865A1 (en) * | 2005-10-05 | 2007-04-12 | Merck Frosst Canada Ltd. | Substituted quinolines as inhibitors of leukotriene biosynthesis |
| AR065093A1 (es) * | 2007-02-05 | 2009-05-13 | Merck Frosst Canada Ltd | Compuestos farmacéuticos inhibidores de la biosintesis de leucotrienos |
| AR068498A1 (es) * | 2007-09-27 | 2009-11-18 | Merck & Co Inc | Compuestos de oxadiazol para inhibicion de biosintesis de leucotrienos |
| JP2013501064A (ja) | 2009-08-04 | 2013-01-10 | アミラ ファーマシューティカルス，インコーポレーテッド | リゾホスファチジン酸受容体アンタゴニストとしての化合物 |
| GB2474120B (en) | 2009-10-01 | 2011-12-21 | Amira Pharmaceuticals Inc | Compounds as Lysophosphatidic acid receptor antagonists |
| EA201390821A1 (ru) | 2010-12-07 | 2013-10-30 | Амира Фармасьютикалс, Инк. | Антагонисты рецепторов лизофосфатидной кислоты и их применение |
| RS57377B1 (sr) | 2010-12-07 | 2018-08-31 | Amira Pharmaceuticals Inc | Policiklični lpa1 antagonist i njegove primene |
| EP2694496A1 (en) | 2011-04-05 | 2014-02-12 | Amira Pharmaceuticals, Inc. | 3- or 5 - bi phenyl - 4 - ylisoxazole - based compounds useful for the treatment of fibrosis, pain, cancer and respiratory, allergic, nervous system or cardiovascular disorders |
| US9260416B2 (en) | 2011-05-27 | 2016-02-16 | Amira Pharmaceuticals, Inc. | Heterocyclic autotaxin inhibitors and uses thereof |
| WO2014031586A2 (en) * | 2012-08-20 | 2014-02-27 | Tallikut Pharmaceuticals, Inc. | Methods for treating cardiovascular diseases |
| CN102924442B (zh) * | 2012-11-15 | 2014-10-29 | 沈阳药科大学 | 含有噻唑环的色满类化合物及其类似物和医药用途 |
| CN103304556B (zh) * | 2013-06-21 | 2016-06-01 | 天津药物研究院有限公司 | 含有苯并吡喃的希夫碱类化合物、其制备方法和用途 |
| SG11201707246YA (en) | 2015-03-06 | 2017-10-30 | Pharmakea Inc | Fluorinated lysyl oxidase-like 2 inhibitors and uses thereof |
| JP6612975B2 (ja) * | 2015-09-24 | 2019-11-27 | ▲貴▼州百▲霊▼企▲業▼集▲団▼制▲薬▼股▲分▼有限公司 | ４−置換クマリン誘導体ならびにその調製法および使用 |
| KR102615565B1 (ko) | 2016-09-07 | 2023-12-18 | 파마케아, 인크. | 리실 옥시다제 유사 2 억제제의 용도 |
| BR112019004517A2 (pt) | 2016-09-07 | 2019-08-13 | Pharmakea, Inc. | formas cristalinas de um inibidor lisil-oxidase-semelhante 2 e métodos de preparação |
| CN108658962B (zh) * | 2017-03-30 | 2021-10-01 | 复旦大学 | 3-取代香豆素呋咱衍生物及其在制备抗多药耐药肿瘤药物中的用途 |
| CN111116506B (zh) * | 2019-12-31 | 2024-03-08 | 浙江大学衢州研究院 | 一种芳巯基二唑类衍生物的合成方法 |
| CN113149979B (zh) * | 2021-03-05 | 2022-11-25 | 朗捷睿(苏州)生物科技有限公司 | 一种8-(苯并噻唑酰胺)取代香豆素类化合物及其制备方法和应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3834860A1 (de) * | 1988-10-13 | 1990-04-19 | Basf Ag | Heterocyclisch substituierte alkoxycumarine, verfahren zu ihrer herstellung und diese enthaltende therapeutische mittel |
| DE4235603A1 (de) * | 1992-10-22 | 1994-04-28 | Basf Ag | Arylalkoxythiocumarine, Verfahren zu ihrer Herstellung und diese enthaltende therapeutische Mittel |
| US5424320A (en) | 1993-06-23 | 1995-06-13 | Merck Frosst Canada, Inc. | Heteroaryl coumarins as inhibitors of leukotriene biosynthesis |
| EP0650964A1 (en) | 1993-11-02 | 1995-05-03 | Duphar International Research B.V | 1 2H-1-benzopyran-2-one-8-yl -piperazine derivatives |
| US5552437A (en) * | 1994-10-27 | 1996-09-03 | Merck Frosst Canada, Inc. | Bisarylcarbinol derivatives as inhibitors of leukotriene biosynthesis |
| US5576338A (en) * | 1995-02-15 | 1996-11-19 | Merck Frosst Canada, Inc. | Bis (biaryl) compounds as inhibitors of leukotriene biosynthesis |
| US6265421B1 (en) | 1997-06-25 | 2001-07-24 | Orion Corporation | Phospholamban inhibitors and a method for increasing coronary flow |
| US6538022B1 (en) * | 1997-09-24 | 2003-03-25 | Orion Corporation | Compounds for deactivating phospholamban function on Ca-ATPase (phopholamban inhibitors) |
| US5968959A (en) * | 1997-12-12 | 1999-10-19 | Orion Corporation | Method for the prevention and treatment of stunned myocardium |
| CA2429008A1 (en) | 2000-07-13 | 2003-01-09 | Takeda Chemical Industries, Ltd. | Lipid-rich plaque regressing agents |
| AU2002221116A1 (en) | 2000-12-11 | 2002-06-24 | Takeda Chemical Industries Ltd. | Medicinal compositions having improved water-solubility |
| WO2004014388A1 (en) * | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | 6,6-fused heteroaryl derivatives as matrix metalloproteinase inhibitors |
| AU2004245146B2 (en) | 2003-06-11 | 2010-01-21 | Merck Frosst Canada Ltd | 7-(1,3-thiazol-2-yl)thio-coumarin derivatives and their use as leukotriene biosynthesis inhibitors |
| AR055041A1 (es) * | 2005-03-23 | 2007-08-01 | Merck Frosst Canada Ltd | Tiadiazoles y oxadiazoles como inhibidores de la sintesis de leucotrienos. composiciones farmaceuticas. |
-
2006
- 2006-03-13 AR ARP060100953A patent/AR055041A1/es not_active Application Discontinuation
- 2006-03-15 TW TW095108809A patent/TWI321130B/zh not_active IP Right Cessation
- 2006-03-16 GT GT200600117A patent/GT200600117A/es unknown
- 2006-03-16 PE PE2006000290A patent/PE20061328A1/es not_active Application Discontinuation
- 2006-03-21 CA CA2600727A patent/CA2600727C/en not_active Expired - Fee Related
- 2006-03-21 AU AU2006227524A patent/AU2006227524B2/en not_active Ceased
- 2006-03-21 EP EP06741360A patent/EP1869031B1/en active Active
- 2006-03-21 CN CNA2006800091517A patent/CN101146802A/zh active Pending
- 2006-03-21 WO PCT/CA2006/000432 patent/WO2006099735A1/en not_active Ceased
- 2006-03-21 CN CN2012100528865A patent/CN102627638A/zh active Pending
- 2006-03-21 JP JP2008502204A patent/JP4109316B1/ja not_active Expired - Fee Related
- 2006-03-21 ES ES06741360T patent/ES2394179T3/es active Active
- 2006-03-21 US US11/886,757 patent/US20090227638A1/en not_active Abandoned
- 2006-03-21 EA EA200702058A patent/EA012704B1/ru unknown
- 2006-03-21 KR KR1020077021981A patent/KR20070113259A/ko not_active Ceased
- 2006-03-21 US US11/385,615 patent/US7553973B2/en active Active
- 2006-03-21 BR BRPI0609687-5A patent/BRPI0609687A2/pt not_active IP Right Cessation
- 2006-03-21 MX MX2007011638A patent/MX2007011638A/es active IP Right Grant
- 2006-03-22 MY MYPI20061254A patent/MY142105A/en unknown
- 2006-03-23 PA PA20068667201A patent/PA8667201A1/es unknown
- 2006-03-23 DO DO2006000069A patent/DOP2006000069A/es unknown
-
2007
- 2007-08-30 ZA ZA200707385A patent/ZA200707385B/xx unknown
- 2007-09-04 IL IL185724A patent/IL185724A0/en unknown
- 2007-09-14 TN TNP2007000348A patent/TNSN07348A1/en unknown
- 2007-09-20 NI NI200700242A patent/NI200700242A/es unknown
- 2007-10-16 CR CR9442A patent/CR9442A/es not_active Application Discontinuation
- 2007-10-17 MA MA30306A patent/MA29398B1/fr unknown
- 2007-10-22 NO NO20075384A patent/NO20075384L/no not_active Application Discontinuation
- 2007-11-20 JP JP2007300093A patent/JP5207711B2/ja not_active Expired - Fee Related
-
2008
- 2008-06-27 US US12/215,499 patent/US20090030048A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20061328A1 (es) | Derivados de oxadiazol o tiadiazol como inhibidores de la biosintesis de leucotrienos | |
| BR0316146A (pt) | Derivados de amida do ácido 3-(2-hidróxifenil)-1h-pirazol-4-carboxìlico como inibidores de hsp90 para o tratamento de câncer | |
| EA201070782A1 (ru) | Производные оксадиазола, активные в отношении сфингозин-1-фосфата(sip) | |
| TW200621156A (en) | Fungicidal composition containing acid amide derivative | |
| MY145140A (en) | Amide derivatives, process for preparation thereof and use thereof as insecticide | |
| PE20131463A1 (es) | Piperidino-dihidrotienopirimidinas sustituidas | |
| TR200400541T4 (tr) | Terapide faydalı tropan türevleri. | |
| NO20044995L (no) | Heterosykliske forbindelser | |
| DK1065204T3 (da) | Bicykliske carbonyl-indolforbindelser som anti-inflammatoriske/analgesiske midler og som COX-2-inhibitorer | |
| ECSP088805A (es) | 2-(piridin-2-il)-pirimidinas como fungicidas | |
| BRPI0312882B8 (pt) | derivados de pleuromutilina e composição farmacêutica | |
| CO4970807A1 (es) | Compuestos de indol 2,3 sustituidos como agentes anti-infla matorios y analgesicos | |
| PE20081781A1 (es) | Agonistas de adrenoreceptores alfa2c funcionalmente selectivos | |
| HUP9903216A2 (hu) | Helyettesített benzamidok, valamint alkalmazásuk hatóanyagként gyógyászati készítményekben | |
| PE20061490A1 (es) | Derivados de ciclohexanosulfonilo como inhibidores del transportador de glicina glyt1 | |
| PE20020906A1 (es) | Inhibidores de peptido-deformilasa | |
| AU2003223340A8 (en) | Certain pharmaceutically useful substituted aminoalkyl heterocycles | |
| AR035110A1 (es) | Compuesto derivado de piperazina, uso del mismo para la preparacion de una composicion farmaceutica, composicion farmaceutica que lo comprende y procedimiento para la preparacion de dicho compuesto | |
| IL190024A0 (en) | Stabilized protease composition | |
| ZA202005507B (en) | 10-(di(phenyl)methyl)-4-hydroxy-8,9,9a,10-tetrahydro-7h-pyrrolo[1 ',2':4,5]pyrazino[1,2-b]pyridazine-3,5-dione derivatives and related compounds as inhibitors of the orthomyxovirus replication for treating influenza | |
| CO5680413A2 (es) | Aminoacidos con afinidad por la proteina c2 delta | |
| ATE486071T1 (de) | Azabicycloä3.1.0ühexan-derivate als modulatoren des dopamin-d3-rezeptors | |
| PE20060353A1 (es) | Combinacion farmaceutica antituberculosa que comprende n-(3-[[4-(3-trifluorometilfenil)piperazinil]metil]-2-metil-5-fenil-pirrolil)-4-piridilcarboxamida | |
| BR0206922A (pt) | Compostos orgânicos | |
| UY26568A1 (es) | Nuevos derivados de amidas heterocíclicas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |